Abstract
Patients in intensive care units (ICU) have a variety of complex problems, often with multiple-organ dysfunction, putting them at an exceptionally high risk of adverse drug reactions because of alteration of usual pathways for drug metabolism and excretion. Prescribing for these patients is therefore very difficult since altered drug excretion, impaired metabolism, altered volumes of drug distribution, and drug interactions are problems that need to be overcome to provide safe and effective therapy. Many of these seriously ill patients acquire complications such as nosocomial infection with resultant impaired systemic hemodynamics which further compromises drug metabolism and elimination. Thus, renal failure in the ICU is an adverse prognostic feature for morbidity and mortality, whether it be part of the underlying illness, or acquired due to therapies of those illnesses.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bennett WM, Elzinga LW, Porter GA (1991) Tubulointerstitial disease and toxic nephropathy. In: Brenner B, Rector F (eds) The Kidney. Saunders, Philadelphia, pp 1430–1496
Rush GF, Smith JH, Newton JF, Hook JB (1984) Chemically induved nephrotoxicity: Role of metabolic activation. Crit Rev Toxicol 13: 99–160
Bennett WM (1989) Mechanisms of aminoglycoside nephrotoxicity Clin Exp Pharmacol Physio116: 1–6
Moestrup SK, Cui S, Vorum H, et al (1995) Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs J Clin Invest 96: 1404–1413
Humes HD (1988) Amnioglycoside nephrotoxicity. Kidney Int 33: 900–911
Burdmann EA, Andoh TF, Lindsley J, Houghton DC, Bennett WM, Porter GA (1994) Urinary enzymes as biomarkers of renal injury in experimental nephrotoxicity of immunosuppressive drugs. Renal Failure: 16: 161–168
Houghton DC, Campbell-Boswell MV, Bennett WM (1987) Myeloid bodies in the renal tubules of humans: Relationship to gentamicin therapy. Clin Nephrol 10: 140–145
Bricker NS, Patton JF (1957) Renal function studies in polycystic disease of the kidneys (with observations on the effects of surgical decompression). N Engl J Med 256: 212–214
Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA (1979) The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure. J Infect Dis 140: 576–580
Barza M, Ioannidis JP, Cappelleri JC, Lau J (1996) Single or multiple daily doses of aminoglycosides: A meta-analysis. Br Med J 312: 338–345
Hatala R, Dinh T, Cook DJ (1996) Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 124: 717–725
Bult J, Franklin CM (1996) Using amphotericin B in the critically ill: A new look at an old drug. J Crit Illness 11: 577–585
Branch RA (1988) Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 148: 2389–2394
Bennett WM, Henrich WL, Stoff JS (1996) The renal effects of non-steroidal anti-inflammatory drugs: Summary and recommendations. Am J Kidney Dis 28: S56 - S62
Bennett WM (1995) The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43: S3 - S7
Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725–1738
Bierer BE, Hollander G, Fruman D, Burakoff SJ (1993) Cyclosporin A and FK506: Molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immuno15: 763–773
Textor SC, Wiesner R, Wilson DJ, et al (1993) Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 55: 1332–1339
Rudnick MR, Berns JS, Cohen RM (1996) Contrast media-associated nephrotoxity. Curr Opin Nephrol Hypertens 5: 127–133
Rudnick MR, Goldfarb S, Wexler L, et al (1995) Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: A randomized trial. Kidney Int 47: 254–261
Solomon R, Werner C, Mann D (1994) Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331: 1416–1420
Textor SC (1990) ACE inhibitors in renovascular hypertension. Cardiovasc Drugs Ther 4: 229–235
Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA (1991) Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115: 513–519
Vogelzang NJ (1991) Nephrotoxicity from chemotherapy: Prevention and management. Oncology 5: 97–112
Zager RA (1994) Acute renal failure in the setting of bone marrow transplantation. Kidney Int 46: 1443–1458
Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ (1989) Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 24: 243–245
Berns JS, Cohen RM, Stumacher RJ, Rudnick MR (1991) Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol 1: 1061–1080
Becker BN, Schulman G (1996) Nephrotoxicity of antiviral therapies. Curr Opin Nephrol Hyper-tens 5: 375–379
Wagstaff AJ, Bryson HM (1994) Foscarnet: A reappraisal of its antiviral activity, pharmavokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48: 199–226
Goa KL, Campoli-Richards DM (1987) Pentamidine isethionate: A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33: 242–258
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Bennett, W.M. (1997). Nephrotoxic Acute Renal Dysfunction. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1997. Yearbook of Intensive Care and Emergency Medicine, vol 1997. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-13450-4_70
Download citation
DOI: https://doi.org/10.1007/978-3-662-13450-4_70
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-13452-8
Online ISBN: 978-3-662-13450-4
eBook Packages: Springer Book Archive